Y-Intercept (HK)’s INmune Bio INMB Stock Holding History

Y-Intercept (HK)’s Portfolio INMB Stock Details INMB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-11,059	Closed	-$130K	–	1626
2024 Q1	$130K	Buy	+11,059	New	+$134K	0.01%	1241

Other funds holding INMB

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return

Praetorian PR Rincon, Puerto Rico $275M AUM 84.95% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

RJFSA

Raymond James Financial Services Advisors St. Petersburg, Florida $75.1B AUM 31.89% 1-Year Est. Return

RPAM

Rhenman & Partners Asset Management Stockholm, Sweden $810M AUM 30.2% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

MCM

MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Y-Intercept (HK)'s INMB Position: Q2 2024 in Review

Y-Intercept (HK) sold out of INmune Bio (INMB) in Q2 2024, closing a stake of 11,059 shares — an estimated $130K sold.

Y-Intercept (HK) first reported a position in INMB in Q1 2024 and held it in 1 quarter. The position peaked at $130K in Q1 2024. 57 funds tracked by Wall St. Rank hold INMB as of Q2 2024.

Y-Intercept (HK) reported no remaining INmune Bio position as of Q2 2024 after selling out during the quarter.
Y-Intercept (HK) sold 11,059 INmune Bio shares in Q2 2024, an estimated $130K.
Y-Intercept (HK) first reported a position in INmune Bio in Q1 2024 and held it in 1 quarter.
Y-Intercept (HK)'s INmune Bio position peaked at $130K in Q1 2024.
57 funds tracked by Wall St. Rank held INmune Bio as of Q2 2024.

Based on Y-Intercept (HK)'s 13F filing for Q2 2024, filed 14 Aug 2024.